Testing a Novel Therapeutic Strategy for Comorbid Post-Traumatic Stress Disorder and Alcohol Use Disorder
Status:
Not yet recruiting
Trial end date:
2025-02-01
Target enrollment:
Participant gender:
Summary
This study evaluates the therapeutic tolerability of the use of Cognitive Processing Therapy
(CPT) with propranolol in participants with Posttraumatic Stress Disorder (PTSD) and Alcohol
Use Disorder (AUD). We are planning to perform an initial proof -of- concept randomized,
placebo- controlled trial evaluating propranolol in participants with PTSD and AUD starting
CPT for 12 weeks with three post-treatment follow ups at week-16, week-20, and week-24.
Participants with current diagnosis of PTSD and AUD seeking treatment will be randomized to
either a propranolol group (n=24) or placebo group (n=24) after enrollment. All participants
will receive CPT for 12 weeks after randomization. Primary outcomes will be measured in both
groups at the end of the study (week 12).